| CLX |
Report |
Net sales |
IN-LINE |
pred ~$1.890B vs. cons $1.899B |
MEDIUM |
| CLX |
Report |
Adjusted diluted EPS |
MISS |
pred ~$1.66 vs. cons $1.690 |
MEDIUM |
| CLX |
Report |
Gross profit |
MISS |
pred ~$800M vs. cons $809M |
MEDIUM |
| CLX |
Guide |
FY27 net sales |
UNCHANGED |
guide ~$7.45B-$7.60B vs. cons $7.521B |
LOW |
| CLX |
Guide |
FY27 adjusted diluted EPS |
UNCHANGED |
guide ~$5.80-$6.05 vs. cons $5.923 |
LOW |
| CLX |
Guide |
FY27 gross-profit trajectory |
UNCHANGED |
guide ~$3.18B-$3.27B vs. cons $3.231B |
LOW |
| CLX |
Guide |
FY27 margin-recovery commentary |
LOWER |
guide slow multi-quarter recovery vs. cons UNVERIFIED |
LOW |
| CLX |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| CLX |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — margin/EPS miss pressures near-term estimates |
LOW |